Efficacy and Safety Overview

Learn about the efficacy and safety data in immunocompromised patients aged 18 years and older.

The efficacy of SHINGRIX was evaluated in one Phase 3 randomized, placebo-controlled, observer-blind study in immunocompromised adults 18 years and older who underwent autologous hematopoietic stem cell transplant (auHSCT) and was also calculated post hoc in another randomized, placebo-controlled, observer-blind study in adults 18 years and older with hematologic malignancies who received their first dose during or within 6 months of completing immunosuppressive chemotherapy.1

See Efficacy Data

The safety profile of SHINGRIX was evaluated in 6 placebo-controlled studies in adults 18 years and older from 5 different immunocompromised populations, including autologous hematopoietic stem cell transplant, hematologic malignancy, renal transplant, solid tumor malignancy, and HIV infection. Solicited local reactions (pain, redness, swelling) and general reactions (fatigue, myalgia, headache, gastrointestinal symptoms, shivering, and fever) were reported more frequently in the SHINGRIX groups compared with placebo.1

See Safety Profile

You may also be interested in:

Incidence of Shingles

Learn about the incidence of shingles in immunocompromised patients aged 18 years and older.

CDC Recommendations

See what CDC says about SHINGRIX.

Reconstitution & Administration

See how you and your staff can reconstitute SHINGRIX in 4 steps.